CBX3 and neoplasm: Thus, the ability of Cbx3/HP1γ-deficient CD8+ T cells to eradicate solid tumors was evaluated using the mouse ID8 or MOSE-LTICv ovarian, B16 melanoma and NB-9464 NBL tumor models.